Black Diamond Therapeutics Announces Changes to Board of Directors
11 Avril 2024 - 2:00PM
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage
oncology company developing MasterKey therapies that target
families of oncogenic mutations in patients with cancers, today
announced that industry veterans Shannon Campbell and Prakash
Raman, Ph.D., have been appointed to the Company’s Board of
Directors. The Company also announced that Wendy Dixon, Ph.D., and
Alex Mayweg, Ph.D., have stepped down as members of its Board of
Directors. These changes became effective as of April 10, 2024.
“On behalf of the board, I am excited to welcome
Shannon and Prakash, both seasoned executives who bring deep and
highly relevant oncology expertise to our board as we advance
BDTX-1535, a potential first and best-in-class fourth-generation
EGFR inhibitor,” said Mark Velleca, M.D., Ph.D., Chief Executive
Officer of Black Diamond Therapeutics. “I would also like to thank
Alex for his many years of support for Black Diamond and Wendy for
her important contributions as a board member.”
"I am thrilled to join the board of Black
Diamond at this pivotal time as the Company advances BDTX-1535
through Phase 2 development, and am excited by its potential to
address the substantial and growing unmet need for patients with
NSCLC in both front-line and later lines of therapy,” said Ms.
Campbell.
Shannon Campbell currently serves as the
Executive Vice President and Chief Commercial Officer at Merus, a
clinical-stage oncology company developing multispecific antibody
therapeutics, where she is responsible for Merus’s global
commercialization strategy and activity. With over 30 years of
biopharmaceutical experience, Ms. Campbell possesses deep expertise
in commercializing transformative medicines globally. Before
joining Merus, Ms. Campbell led the U.S. Solid Tumor Franchise at
Novartis, and previously led the US Oncology Business Unit at Bayer
HealthCare Pharmaceuticals. Earlier in her career she held
positions of increasing responsibility at Abbott Labs and Pharmacia
heritage companies. Ms. Campbell holds a Bachelor of Science degree
from Ithaca College and has completed leadership, strategy, and
finance programs at the University of Michigan Ross School of
Business, IMD, Harvard Business School, and The Wharton School,
University of Pennsylvania.
"I am extremely impressed by Black Diamond’s
development progress with both BDTX-1535 and BDTX-4933, and look
forward to partnering with the board and the management team to
maximize the potential of these novel compounds,” said Dr.
Raman.
Prakash Raman, Ph.D., has over two decades of
biopharmaceutical business development and executive leadership
experience, blending his scientific background, program and
portfolio management and strong business development experience. He
currently serves as Chief Executive Officer of a stealth biopharma
company working on novel protein therapeutics in Oncology and
Immunology. Previously, he was President and Chief Executive
Officer of Ribon Therapeutics, a biopharmaceutical company focused
on small molecule drugs for Oncology and Immunology. Prior to
joining Ribon, he served as Senior Partner, Chief Business
Development Officer at Flagship Pioneering. Before Flagship, he was
Vice President, Global Head of Novartis Institutes for Biomedical
Research Business Development and Licensing. Dr. Raman was
instrumental in forging key collaborations in immuno-oncology,
executing many out-licensing opportunities, guiding acquisitions,
and led cross-functional drug discovery and early development
project teams. Dr. Raman’s previous roles include Senior Scientist
at Millennium Pharmaceuticals and post-doctoral fellow at The
Scripps Research Institute. He completed his undergraduate work at
the Indian Institute of Technology, Bombay, and received his Ph.D.
in Organic and Medicinal Chemistry from the University of
Wisconsin-Madison.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage
oncology company focused on the development of MasterKey therapies
that address families of oncogenic mutations in clinically
validated targets. The Company’s MasterKey therapies are designed
to address broad genetically defined patient populations, overcome
resistance, minimize wild-type mediated toxicities, and be brain
penetrant to treat CNS disease. The Company is advancing two
clinical-stage programs: BDTX-1535, a brain-penetrant
fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant
NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey
inhibitor targeting KRAS, NRAS and BRAF alterations in solid
tumors. For more information, please visit
www.blackdiamondtherapeutics.com.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to, statements regarding the continued development and
advancement of BDTX-1535 and BDTX-4933, and the potential of
BDTX-1535 to benefit patients with NSCLC. Any forward-looking
statements in this statement are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. Risks that contribute to the uncertain
nature of the forward-looking statements include those risks and
uncertainties set forth in its Annual Report on Form 10-K for the
year ended December 31, 2023, filed with the United States
Securities and Exchange Commission and in its subsequent filings
filed with the United States Securities and Exchange Commission.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. The Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
ContactsFor Investors:Mario Corso, Head of
Investor Relations, Black Diamond Therapeuticsmcorso@bdtx.com
For Media:media@bdtx.com
Black Diamond Therapeutics (NASDAQ:BDTX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Black Diamond Therapeutics (NASDAQ:BDTX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024